Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant in breast cancer patients with hot flashes
NCT06440967Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of fezolinetant in hot flashes, sponsored by Astellas Pharma. Started Jul 2024; status: active, not recruiting.
02
Drugs
fezolinetant
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT06440967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440967.